Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 15;11:16866. doi: 10.1038/s41598-021-96351-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Therapeutic efficacy of lapatinib-loaded hiPSC-platelets in vivo.(A) Representative BLI images of xenografted BBM1-derived tumor-bearing female NOD/SCID mice treated with vehicle (control), free lapatinib, and non-loaded and lapatinib-loaded hiPSC- and donor-derived platelets every 3 days. (B) Bioluminescence was quantified for BBM1-derived tumor-bearing female NOD/SCID mice throughout the experiment, as indicated. Mice were injected with vehicle (control), free lapatinib, and non-loaded and lapatinib-loaded hiPSC- and donor-derived platelets every 3 days. * indicates p < 0.05, ** indicates p < 0.001. Each group contains n = 7 mice. (C) Overall survival of variously treated BBM1-derived tumor-bearing female NOD/SCID mice. Control vs. non-loaded hiPSC- and donor-derived platelets, ns (non-significant); control vs. lapatinib, p < 0.05; control vs. lapatinib-loaded hiPSC- and donor-derived platelets, p < 0.001. (D) Tumor-seeding capability of BBM1 cells in female NOD/SCID mice pre-treated with vehicle (control), and non-loaded and lapatinib-loaded hiPSC and donor-derived platelets. (E) Tumor volume of BBM-derived tumor-bearing NOD/SCID mice treated with vehicle, free lapatinib, and non-loaded and lapatinib-loaded hiPSC- and donor-derived platelets, measured at 40 days post-implant (n = 7 per group). Control vs. lapatinib, p < 0.05; control vs. free lapatinib, * p < 0.05; non-loaded platelets vs. lapatinib-loaded platelets, ** p < 0.001.